Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Werewolf Therapeutics (HOWL) EBT Margin (2022 - 2024)

Werewolf Therapeutics (HOWL) has disclosed EBT Margin for 3 consecutive years, with 135373.33% as the latest value for Q4 2024.

  • On a quarterly basis, EBT Margin fell 13473380.0% to 135373.33% in Q4 2024 year-over-year; TTM through Sep 2025 was 486173.33%, a 48438982.0% decrease, with the full-year FY2024 number at 3767.21%, down 358556.0% from a year prior.
  • EBT Margin was 135373.33% for Q4 2024 at Werewolf Therapeutics, down from 1601.84% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 62.79% in Q2 2023 to a low of 135373.33% in Q4 2024.
  • A 3-year average of 14100.75% and a median of 301.12% in 2022 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: surged 29582bps in 2023, then tumbled -13473380bps in 2024.
  • Werewolf Therapeutics' EBT Margin stood at 164.77% in 2022, then tumbled by -288bps to 639.53% in 2023, then crashed by -21068bps to 135373.33% in 2024.
  • Per Business Quant, the three most recent readings for HOWL's EBT Margin are 135373.33% (Q4 2024), 1601.84% (Q2 2024), and 2182.21% (Q1 2024).